Helen Q. Huang

发表

Incorporation of bevacizumab in the primary treatment of ovarian cancer

Jeffrey M. Fowler, Michael J. Birrer, Robert S. Mannel, 2012 .

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

R. Ashfaq, P. Sabbatini, J. Chan, 2017, The Lancet. Oncology.

Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.

W. E. Richards, D. Matei, D. Mutch, 2021, Gynecologic oncology.

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

W. E. Richards, D. Matei, W. Small, 2019, The New England journal of medicine.

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

B. Monk, D. Cella, P. Rose, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

B. Monk, D. Cella, Helen Q. Huang, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

A. Secord, T. Rutherford, T. Herzog, 2017, Gynecologic oncology.

Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study.

D. Cella, Joan L. Walker, N. Spirtos, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275

N. Horowitz, D. Miller, K. Moxley, 2020, Gynecologic oncology.

Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study

R. Burger, D. Cella, P. Disaia, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

R. Burger, Joan L. Walker, D. Armstrong, 2006, The New England journal of medicine.

A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study.

B. Monk, D. Cella, K. Gil, 2010, Journal of pain and symptom management.

Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials

B. Monk, D. Cella, P. Rose, 2009, Cancer.

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

R. Burger, Joan L. Walker, D. Armstrong, 2006, Gynecologic Oncology.

Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.

D. Cella, A. Montag, N. Spirtos, 2010, Gynecologic oncology.

Patient Reported Outcomes in a Practice Changing Randomized Trial of Bevacizumab in the Treatment of Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study

L. Ramondetta, H. Michael, M. Method, 2015 .

Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.

B. Monk, D. Miller, J. Fiorica, 2006, Gynecologic oncology.

Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study

B. Monk, K. Robison, L. Ramondetta, 2020, International Journal of Gynecological Cancer.

Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.

Danielle M. Enserro, B. Monk, R. Burger, 2018 .

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

B. Monk, R. Burger, M. Birrer, 2017, The Lancet.

GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE).

D. Alberts, R. Barakat, A. Hutson, 2019, Gynecologic oncology.

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

D. Mutch, A. Secord, D. Miller, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

B. Monk, R. Burger, M. Birrer, 2011, The New England journal of medicine.

Factors Associated with Deciding between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study

R. Wenham, M. Greene, R. Moser, 2017 .

Improved survival with bevacizumab in advanced cervical cancer.

Michael W Sill, Helen Huang, B. Monk, 2014, The New England journal of medicine.

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

B. Monk, M. Birrer, S. Rubin, 2016, The New England journal of medicine.

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

D. Cella, D. Miller, Takashi Matsumoto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

R. L. Hollis, H. Gabra, A. Secord, 2022, The Lancet.

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Danielle M. Enserro, Jae-Weon Kim, P. Sabbatini, 2019, The New England journal of medicine.

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Danielle M. Enserro, B. Monk, R. Burger, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients with Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer

H. Gabra, A. Secord, R. Coleman, 2019, Gynecologic Oncology.

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.

D. Cella, Joan L. Walker, M. Zevon, 2021, Gynecologic oncology.

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.

Jae-Weon Kim, W. Small, D. Miller, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sexual Function of Patients With Endometrial Cancer Enrolled in the Gynecologic Oncology Group LAP2 Study

D. Cella, Joan L. Walker, L. Wenzel, 2012, International Journal of Gynecologic Cancer.

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

B. Monk, R. Burger, R. Mannel, 2013, Gynecologic oncology.

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study

B. Monk, M. Birrer, L. Ramondetta, 2023, Gynecologic oncology.

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).

B. Monk, L. Ramondetta, L. Landrum, 2015, The Lancet. Oncology.

B. Monk, D. Cella, L. Ramondetta, 2010, Gynecologic oncology.

Final Overall Survival of the Phase III Randomised Trial of Chemotherapy with and without Bevacizumab for Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study

B. Monk, R. Burger, M. Birrer, 2017 .

Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.

B. Monk, D. Cella, L. Wenzel, 2012, Gynecologic oncology.

The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study.

K. Gil, D. Armstrong, L. Wenzel, 2012, Gynecologic oncology.

Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.

D. Alberts, A. Hanlon, L. Havrilesky, 2015, Gynecologic oncology.

A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.

W. Richards, D. Mutch, A. Secord, 2019, Journal of Clinical Oncology.

D. Cella, Joan L. Walker, D. Armstrong, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

P. Fracasso, P. Thaker, S. Waggoner, 2012, Gynecologic oncology.

Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study.

D. Cella, Joan L. Walker, D. Armstrong, 2008, Gynecologic oncology.

Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

D. Cella, Joan L. Walker, M. Zevon, 2018, Gynecologic oncology.

Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.

R. Wenham, M. Greene, R. Moser, 2017, Gynecologic oncology.

GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function.

W. E. Richards, D. Alberts, R. Barakat, 2020, Gynecologic oncology.

Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study

R. Burger, H. Hoffman, W. Mojica, 2005, BMJ : British Medical Journal.

Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study

D. Cella, G. Fleming, M. Brady, 2006, International Journal of Gynecologic Cancer.

Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemo

P. Sabbatini, Byoung-Gie Kim, R. Coleman, 2015 .

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved survival with bevacizumab in advanced cervical cancer.

B. Monk, L. Ramondetta, L. Landrum, 2014, The New England journal of medicine.

R. Ashfaq, P. Sabbatini, J. Chan, 2017, The Lancet. Oncology.

LBA26FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE III RANDOMIZED TRIAL OF CHEMOTHERAPY WITH AND WITHOUT BEVACIZUMAB FOR ADVANCED CERVICAL CANCER: A NRG ONCOLOGY - GYNECOLOGIC ONCOLOGY GROUP STUDY

B. Monk, L. Ramondetta, L. Landrum, 2014 .

Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: A Gynecologic Oncology Group (GOG) study

B. Monk, L. Ramondetta, L. Landrum, 2014 .

High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: A Gynecologic Oncology Group (GOG) study

B. Monk, L. Ramondetta, L. Landrum, 2014 .

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

B. Monk, M. Birrer, S. Rubin, 2016, The New England journal of medicine.

Measurement of vaginal length: reliability of the vaginal sound—a Gynecologic Oncology Group Study

D. Cella, M. Shahin, E. Sobel, 2006, International Journal of Gynecologic Cancer.

Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.

R. Wenham, M. Greene, R. Moser, 2019, Gynecologic oncology.

Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.

B. Monk, R. Burger, L. Wenzel, 2015, Gynecologic oncology.

A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study

R. Burger, D. Cella, P. Disaia, 2017 .